Clinical Trials Resource Center


September 1, 2008

NeuroDiscovery released positive results from a phase II trial of NSL-101 for the treatment of periodontitis. This double-blind, randomized, controlled study enrolled 50 subjects in Lima, Peru. The subjects received NSL-101 gel (5%) or lidocaine (5%), the standard analgesic, during scaling and root planing procedures. The primary endpoint was pain intensity, as measured by patients on the Visual Analog Scale (VAS) and Verbal Rating Scale (VRS). Overall, the efficacy of NSL-101 was comparable to that of lidocaine. NSL-101 produced numerically superior analgesia and duration of action compared to lidocaine, however, the differences were not statistically significant. Treatment was well tolerated and there were no reports of drug-related serious adverse events. Based on the results, NeuroDiscovery plans to continue with the development of NSL-101.

Related Medical Areas

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.